Non-alcoholic fatty liver disease (NAFLD) has become one of the most prominent forms of
chronic liver disease worldwide, reflecting the epidemic of global obesity. Those with the …

Introduction 13C‐breath tests are valuable, noninvasive diagnostic tests that can be widely
applied for the assessment of gastroenterological symptoms and diseases. Currently, the …

Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of histopathologic features,
ranging from isolated hepatic steatosis, to steatohepatitis with evidence of hepatocellular …

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease,
affecting approximately 25% of the general population worldwide, and is forecasted to …

Breath research has almost invariably focussed on the identification of endogenous volatile
organic compounds (VOCs) as disease biomarkers. After five decades, a very limited …

Nonalcoholic steatohepatitis (NASH) is increasing in prevalence, yet its consequences for
liver function are unknown. We studied ureagenesis, an essential metabolic liver function of …

Assessment of the liver function, and the need of constant monitoring of the organ's capacity,
concerns not only patients with primary liver diseases, but also those at risk of hepatopathies …

Non‐alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder whose
prevalence is strongly linked to the current epidemic of obesity in many western countries …

Background Non-alcoholic fatty liver disease (NAFLD) is a major health concern affecting
25% of the world's population. It is generally held that a fatty liver does not influence liver …

The maximal liver function capacity (LiMAx) test, a novel 13 C-methacetin breath test, has
proven clinical validity in determining hepatic metabolic capacity. In contrast to prior 13 C …